Hemophilia B Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk

The Key Hemophilia B Companies in the marlet include - Pfizer, CSL Behring/uniQure, HEMA Biologics/LFB, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, and others.

The Hemophilia B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemophilia B pipeline products will significantly revolutionize the Hemophilia B market dynamics.

DelveInsight's "Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hemophilia B market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Hemophilia B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia B Market Insights [https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hemophilia B Market Report:

*
The Hemophilia B market size was valued ~USD 3,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In December 2024, The first-in-human Phase 1/2 clinical trial for BE-101, Be Biopharma's B-cell treatment candidate for hemophilia B, is now recruiting patients at two U.S. sites. BE-101 is a pioneering therapy designed to address the ongoing unmet needs of hemophilia B patients, particularly those who continue to experience frequent bleeding episodes. The two-part Phase 1/2 trial, named BeCoMe-9 (NCT06611436), aims to evaluate the safety and clinical effectiveness of a single intravenous infusion of BE-101 in adults with moderately severe to severe hemophilia B.

*
In April 2024, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ Trademark (fidanacogene elaparvovec-dzkt) for treating adults with moderate to severe hemophilia B. This approval is for individuals who are on factor IX (FIX) prophylaxis therapy, have experienced life-threatening hemorrhages, or suffer from recurrent, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid, as identified by an FDA-approved test. BEQVEZ is a one-time treatment aimed at allowing people with hemophilia B to produce FIX on their own, eliminating the need for frequent intravenous FIX infusions, which are often required several times a week or month.

*
In February 2024, Intellia Therapeutics and Regeneron are set to initiate the first human trial of a CRISPR/Cas9-based Factor 9 (F9) gene-editing therapy for hemophilia B by mid-year. This announcement, made in an Intellia financial report, comes after the recent approval by the U.S. Food and Drug Administration (FDA) of the investigational new drug (IND) application filed by the two companies.

*
Replacement therapy is the most widely used treatment for hemophilia B. In the U.S., several recombinant factor IX products are available, including BeneFIX, RIXUBIS, IXINITY, ALPROLIX, IDELVION, and REBINYN. Additionally, bypassing agents like Feiba, Novoseven, and SEVENFACT, along with human plasma-derived coagulation factor IX products such as AlphaNine SD and Mononine, have also received FDA approval.

*
In 2023, the United States had the highest number of diagnosed prevalent cases of hemophilia B among the 7MM, with an estimated 4,000 cases. This number is anticipated to rise over the forecast period.

*
In 2023, France reported the highest number of diagnosed prevalent cases of hemophilia B among the EU4 and the UK, whereas Germany had the lowest number of cases.

*
Estimates show that in the US, hemophilia B was most commonly found in the 19-44 years age group, representing approximately 35% of the total cases.

*
Key Hemophilia B Companies: Pfizer, CSL Behring/uniQure, HEMA Biologics/LFB, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, and others

*
Key Hemophilia B Therapies: BEQVEZ (fidanacogene elaparvovec-dzkt), HEMGENIX (etranacogene dezaparvovec-drlb), SEVENFACT, Marstacimab (PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, Serpin, and others

*
The lowest prevalent population of Hemophilia B were recorded in Spain

Hemophilia B Overview

Hemophilia B is a rare genetic bleeding disorder caused by a deficiency or dysfunction of clotting factor IX, a protein essential for blood clotting. It is an inherited condition, typically passed down through the X chromosome, affecting mostly males, while females are usually carriers. Individuals with Hemophilia B experience prolonged bleeding after injuries, surgeries, or spontaneously in severe cases. Common symptoms include frequent bruising, joint bleeds, and internal bleeding. Treatment involves replacing the missing factor IX through regular infusions or advanced gene therapies. Early diagnosis and proper management are crucial to improving quality of life and preventing complications.

Get a Free sample for the Hemophilia B Market Report:

https://www.delveinsight.com/report-store/hemophilia-b-market [https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hemophilia B Market

The dynamics of the Hemophilia B market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Hemophilia B Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hemophilia B Epidemiology Segmentation:

The Hemophilia B market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hemophilia B

*
Prevalent Cases of Hemophilia B by severity

*
Gender-specific Prevalence of Hemophilia B

*
Diagnosed Cases of Episodic and Chronic Hemophilia B

Download the report to understand which factors are driving Hemophilia B epidemiology trends @ Hemophilia B Epidemiological Insights [https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hemophilia B Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched during the study period. The analysis covers Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hemophilia B Therapies and Key Companies

*
BEQVEZ (fidanacogene elaparvovec-dzkt): Pfizer

*
HEMGENIX (etranacogene dezaparvovec-drlb): CSL Behring/uniQure

*
SEVENFACT: HEMA Biologics/LFB

*
Marstacimab (PF-06741086): Pfizer

*
SPK-9001: Pfizer/Spark Therapeutics

*
Fitusiran: Sanofi/ Alnylam Pharmaceuticals

*
AMT-061: CSL Behring/ uniQure

*
Concizumab: Novo Nordisk

*
FLT180a: Freeline Therapeutics

*
SerpinPC: ApcinteX

To know more about Hemophilia B treatment, visit @ Hemophilia B Medications [https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hemophilia B Market Drivers

*
Popularity of Gene Therapy

*
Increased Focus on Prophylactic Treatment

*
Development of Novel Treatments with extended half-life

Hemophilia B Market Barriers

*
High Cost of Treatment

*
Inconvenience and Scheduling Barriers

*
Lack of Skilled Healthcare Professionals

Scope of the Hemophilia B Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hemophilia B Companies: CSL Behring/uniQure, HEMA Biologics/LFB, Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, and others

*
Key Hemophilia B Therapies: BEQVEZ (fidanacogene elaparvovec-dzkt), HEMGENIX (etranacogene dezaparvovec-drlb), SEVENFACT, Marstacimab (PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, Serpin, and others

*
Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies

*
Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hemophilia B Unmet Needs, KOL's views, Analyst's views, Hemophilia B Market Access and Reimbursement

Discover more about therapies set to grab major Hemophilia B market share @ Hemophilia B Treatment Landscape [https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hemophilia B Market Report Introduction

2. Executive Summary for Hemophilia B

3. SWOT analysis of Hemophilia B

4. Hemophilia B Patient Share (%) Overview at a Glance

5. Hemophilia B Market Overview at a Glance

6. Hemophilia B Disease Background and Overview

7. Hemophilia B Epidemiology and Patient Population

8. Country-Specific Patient Population of Hemophilia B

9. Hemophilia B Current Treatment and Medical Practices

10. Hemophilia B Unmet Needs

11. Hemophilia B Emerging Therapies

12. Hemophilia B Market Outlook

13. Country-Wise Hemophilia B Market Analysis (2020-2034)

14. Hemophilia B Market Access and Reimbursement of Therapies

15. Hemophilia B Market Drivers

16. Hemophilia B Market Barriers

17. Hemophilia B Appendix

18. Hemophilia B Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-b-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-pfizer-spark-therapeutics-sanofi-alnylam-pharma-csl-behring-uniqure-novo-nordisk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.